The survival and immune reprogramming data may reframe clinical development strategy around sequencing and durability rather than response rate. Traders should monitor for upcoming trial expansions, partnership announcements, or FDA guidance on trial design for accelerated approval pathways.
INKT drugs
INKT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $14.21entry
- T+1 · 7mo ago −9.78%α −9.59% · $12.82
- T+5 · 7mo ago −22.94%α −23.50% · $10.95
- T+20 · 6mo ago −26.04%α −31.41% · $10.51
- T+60 · 4mo ago −19.70%α −25.85% · $11.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combination with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer, showing a 77% disease control rate and improved survival with an induction strategy. Despite missing the primary endpoint of ORR, the durable responses and immune activation support further development. The data are being presented at AACR 2026.
Key Facts
- Phase II trial (n=17) showed 77% disease control rate (DCR) in PD-1 refractory gastroesophageal cancer patients.
- Induction strategy with agenT-797 led to median PFS of 6.9 months vs. 3.5 months (HR 0.19; p=0.015) and median OS of 9.5 vs. 5.2 months.
- 43% of induction-treated patients were alive at 12 and 18 months, compared to 20% and 0% in non-induction cohort.
- Trial did not meet primary endpoint of ORR, but durable disease control and survival are emphasized as key benefits.
- Biomarker analyses show immune activation, T-cell infiltration, and tertiary lymphoid structure formation.
Financial Impact
High clinical significance despite small sample size; potential to accelerate development and attract partnerships.
Risk Factors
- Small trial size (n=17) limits statistical power and generalizability.
- Primary endpoint (ORR) not met, which may raise skepticism among some investors.
- Safety profile includes immune-related adverse events such as colitis and hepatitis.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276455 |
Track record
21 reports on INKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers